Topcon 3D OCT-1000 Optical Coherence Tomography System
Launched by TOPCON MEDICAL SYSTEMS, INC. · Nov 14, 2008
Trial Information
Current as of June 20, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • Retinal Disease Study
- No Retinal Disease:
- Inclusion Criteria:
- • Male or female
- • Between 18 and 80 years of age
- • Either eye, but only one eye per subject will be enrolled
- • Topcon image quality factor ≥ 45 or Stratus signal strength ≥ 5.
- Exclusion Criteria:
- • Any known ocular disease
- • Any systemic disease that could result in ocular manifestations such as hypertension, diabetes, heart disease, etc.
- • Topcon image quality factor ≤ 44 or Stratus signal strength \< 5.
- • Retinal Disease
- Inclusion Criteria:
- • Male or female
- • Between 18 and 80 years of age
- • Either eye, but only one eye per subject will be enrolled
- • Symptoms consistent with one of the following retinal diseases: diabetic macular edema, cystoid macular edema, epiretinal membrane, macular hole, wet AMD and dry AMD for which OCT imaging is warranted. At lease one (1) case each of these diseases will be included in the study
- • A range of retinal thickness will be included
- • Topcon image quality factor ≥ 45 or Stratus signal strength ≥ 5.
- Exclusion Criteria:
- • Presence of glaucoma
- • Topcon image quality factor ≤ 44 or Stratus signal strength \< 5.
About Topcon Medical Systems, Inc.
Topcon Medical Systems, Inc. is a leading provider of advanced ophthalmic equipment and technology, dedicated to enhancing the diagnosis and treatment of eye care conditions. With a commitment to innovation and quality, Topcon develops a comprehensive range of diagnostic instruments and software solutions that empower eye care professionals to deliver superior patient care. The company actively engages in clinical trials to advance the field of ophthalmology, ensuring that their products meet the highest standards of efficacy and safety. Through collaboration with healthcare providers and researchers, Topcon aims to improve patient outcomes and drive advancements in vision science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bronxville, New York, United States
New York, New York, United States
New York, New York, United States
New York, New York, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials